These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 15272916

  • 1. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
    Cozzi R, Attanasio R, Lodrini S, Lasio G.
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
    [Abstract] [Full Text] [Related]

  • 2. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.
    Mattar P, Alves Martins MR, Abucham J.
    Neuroendocrinology; 2010 Aug; 92(2):120-7. PubMed ID: 20802256
    [Abstract] [Full Text] [Related]

  • 3. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA.
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [Abstract] [Full Text] [Related]

  • 4. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
    Jallad RS, Bronstein MD.
    Neuroendocrinology; 2009 Mar; 90(1):82-92. PubMed ID: 19439914
    [Abstract] [Full Text] [Related]

  • 5. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Pico Alfonso AM, Pynka S, Racz K, Schopohl J, Tabarin A, Valimaki MJ, Group for Lanreotide Autogel Long-Term Study on Acromegaly.
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.
    Selvarajah D, Webster J, Ross R, Newell-Price J.
    Eur J Endocrinol; 2005 Apr; 152(4):569-74. PubMed ID: 15817912
    [Abstract] [Full Text] [Related]

  • 7. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [Abstract] [Full Text] [Related]

  • 8. Cabergoline in the treatment of acromegaly: a study in 64 patients.
    Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
    Suda K, Inoshita N, Iguchi G, Fukuoka H, Takahashi M, Nishizawa H, Yamamoto M, Yamada S, Takahashi Y.
    Endocr J; 2013 Feb; 60(4):507-15. PubMed ID: 23291436
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M, Gussoni G, Cuttica CM, Giordano G.
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
    Ronchi CL, Boschetti M, Degli Uberti EC, Mariotti S, Grottoli S, Loli P, Lombardi G, Tamburrano G, Arvigo M, Angeletti G, Boscani PF, Beck-Peccoz P, Arosio M, Italian Multicenter Autogel Study Group in Acromegaly.
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
    [Abstract] [Full Text] [Related]

  • 12. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jiménez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F, Webb SM.
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.
    Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G, Colao A.
    Pituitary; 1999 Nov; 1(2):115-20. PubMed ID: 11081189
    [Abstract] [Full Text] [Related]

  • 14. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
    Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G.
    Eur J Endocrinol; 1999 Sep; 141(3):267-71. PubMed ID: 10474124
    [Abstract] [Full Text] [Related]

  • 15. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G.
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [Abstract] [Full Text] [Related]

  • 16. Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?
    Cozzi R, Attanasio R, Grottoli S, Pagani G, Loli P, Gasco V, Pedroncelli AM, Montini M, Ghigo E.
    J Endocrinol Invest; 2004 Dec; 27(11):1040-7. PubMed ID: 15754736
    [Abstract] [Full Text] [Related]

  • 17. [Novel pharmacologic therapies in acromegaly].
    Góth M, Hubina E, Kovács L, Szabolcs I.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [Abstract] [Full Text] [Related]

  • 18. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G.
    Clin Endocrinol (Oxf); 2005 Sep 12; 63(3):342-9. PubMed ID: 16117824
    [Abstract] [Full Text] [Related]

  • 19. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
    Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP, Grossman AB.
    Clin Endocrinol (Oxf); 2000 Dec 12; 53(6):719-24. PubMed ID: 11155094
    [Abstract] [Full Text] [Related]

  • 20. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD.
    Clin Endocrinol (Oxf); 2005 Aug 12; 63(2):168-75. PubMed ID: 16060910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.